Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Spitzer on Plan B

This article was originally published in The Tan Sheet

Executive Summary

New York Attorney General Eliot Spitzer "will sign into law" a bill that would allow for pharmacy access to Barr Labs' emergency contraceptive Plan B if he is elected as the state's governor later this year, Spitzer stated in a recent speech. His campaign for women's health rights has earned him the endorsement of the pro-choice advocacy groups NARAL and Planned Parenthood. Current Gov. George Pataki (R) vetoed pharmacy access legislation in August after it was passed by the state legislature (1"The Tan Sheet" Aug. 8, 2005, In Brief). "This bill should not have been vetoed," Spitzer states. "We need to pass that bill again." Separately, Barr Pharmaceuticals will be added to the S&P 500 index effective Feb. 24, according to a Feb. 21 announcement. Barr will replace Scientific-Atlanta, which is being acquired by Cisco Systems...

You may also be interested in...

Pataki vetoes OTC Plan B

New York Gov. George Pataki (R) vetoed a bill that would have provided OTC access without parental consent to the emergency contraceptive Plan B (levonorgestrel .75 mg) Aug. 4. The "Unintended Pregnancy Prevention Act" (S 3661) passed the state Senate June 22. Pataki cited lack of protection for minors in his decision and voiced concerns that the bill "lacks several other safeguards." The Family Planning Advocates of New York State called the governor's decision "tragic." Pataki's decision follows Massachusetts Gov. Mitt Romney's (R) July 25 veto of a similar measure...

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts